• Biotech Holdings (Biotech) has its office and plant in the Greater Vancouver area, in British Columbia, Canada.
• Biotech became a public company in 1995 on taking over a public shell trading on the Alberta Stock Exchange
• In May 1996, Biotech shares began trading on the Over the counter Exchange (OTCBB) in the United States
• Biotech Holdings shares now trade on the Toronto Stock Exchange's Venture Board (TSXV) as BIO.V (52-week range $.05-.55) and on the Over the Counter Bulleting board as BIOHF.OB ( 52-week range $.055 - $.42)
• Outstanding shares: approximately 92 million shares
• Publicly held float: approximately 70 million shares
• Financial and other public information available on sedar.com and on the investor info page of this website
• Biotech Holdings has developed a new drug for Type II Diabetes
• Biotech Holdings' business is focused on production and distribution of this anti-diabetic medication
• The drug, trade-marked as Sucanon and Diab II, has been proven effective in clinical trials.
• Sucanon has been approved by regulatory authorities in Mexico and is widely sold in that country including by Costco Mexico and Wal-Mart Mexico
• Sucanon is also available by internet to Type II Diabetics in North America and elsewhere who are buying for personal use.
  .

Officers and Directors

Mr. Robert B. Rieveley, President, Chief Executive Officer & Chairman
Mrs. Gale V. Belding, Executive Vice-President & Director
Mr. Lorne D. Brown, Chief Financial Officer
Mr. Luis M. Ornelas Lopez, Vice-President Latin American Operations
Ross M. Wilmot, C.A., Director; Wilmot is a chartered Accountant (CA) and a director or officer of various public companies;
Mr. Johan de Rooy, FCA, Director
Mrs. Cheryl Rieveley, Director
Art Cowie, Director;

Corporate Facts

Auditors:
Sadovnick Telford + Skov
(604)688-7800

Legal Counsel:
Borden Ladner Gervais
(403)232-9500

Transfer Agent:
Pacific Corporate Trust
(604)689-9853